Juvenile indication for Orencia
Executive Summary
FDA approves Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacep) for moderately to severely active polyarticular juvenile iodiopathic arthritis in pediatric patients six years and older, April 8. The same day, Bristol and Repligen reach an out-of-court settlement regarding royalties due on U.S. sales of the drug. The settlement includes $5 million in past royalties to Repligen and the University of Michigan, the original owner of the patent covering anti-CTLA-4 antibodies. Orencia enters a market that includes Abbott's tumor necrosis factor inhibitor Humira (adalimumab), which was approved in February
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.